Bellus Health Inc   Report issue

For profit Phase 2 Phase 3
Founded: Laval QE Canada (2010)
Status: Acquired by GlaxoSmithKline (2023)

Organization Overview

First Clinical Trial
2010
NCT00035334
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bellus Health Inc

Active Ingredients

Drugs in Phase 3 Trials (2)

eprodisate (Kiacta) (2 trials)

tramiprosate (4 trials)

Drugs in Phase 2 Trials (1)

camlipixant (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 3)

Cerebral Amyloid Angiopathy (Phase 2)

Cerebral Amyloid Angiopathy, Familial (Phase 2)

Cough (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Digestive System Diseases (Phase 3)

Eczema (Phase 2)

Gastrointestinal Diseases (Phase 3)

Hemorrhage (Phase 2)

Kidney Diseases (Phase 3)

Metabolic Syndrome (Phase 2)

Neoplasm Metastasis (Phase 3)

Nephrosis (Phase 3)

Nephrotic Syndrome (Phase 3)

Nervous System Diseases (Phase 2)

Pruritus (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 3